Galmed Pharma (GLMD) Misses Q2 EPS by 4c

Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• MIND Technology (MIND) Misses Q1 EPS by 5c
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital